ResMed (RMD) Stewardship presentation summary
Event summary combining transcript, slides, and related documents.
Stewardship presentation summary
25 Sep, 2026Fiscal 2026 performance and strategy
Achieved approximately $5.7B in revenue with 8% constant currency growth and 17% non-GAAP EPS growth.
Generated $1.65B in free cash flow, investing in business growth and shareholder returns.
Board and management are aligned on executing the 2030 strategy, aiming to empower 500M people globally.
Focus areas include sleep health, breathing health, and health tech at home, with digital solutions driving improved outcomes.
Sustainability initiatives target minimizing environmental footprint and developing durable patient solutions.
Governance and board structure
Board comprises 10 members, 8 of whom are independent, with annual elections and diverse backgrounds.
Carol Burt appointed Lead Independent Director, succeeding Ron Taylor after his retirement.
Four board committees oversee audit, compensation, compliance, and governance, all chaired by independents.
Board actively oversees strategy, risk management, and participates in director education on key topics.
PwC selected as new independent auditor, replacing KPMG after 32 years, with a smooth transition.
Human capital and leadership
Over 11,300 employees worldwide, with a 13% turnover rate and emphasis on diversity and engagement.
Leadership team combines long-tenured and new executives, supporting growth and strategic execution.
Compensation programs emphasize pay for performance, aligning management and shareholder interests.
Executive compensation is competitive with US med tech peers, balancing short- and long-term incentives.
Latest events from ResMed
- Strong FY26 performance funds growth and returns as board and auditor leadership transition.RMD
Proxy filing - Board backs all 10 director nominees, auditor ratification, and advisory say-on-pay approval.RMD
Proxy filing - Revenue rose 7% core CC, EPS 14%, and shareholder returns topped $1.0B.RMD
Q1 2027 - Shareholders were asked to elect 10 directors, ratify KPMG, and approve executive pay.RMD
Proxy Filing - Ten director elections, KPMG ratification, and advisory votes anchor the ballot.RMD
Proxy Filing - Board backs all three proposals: elect 11 directors, ratify KPMG and approve say-on-pay.RMD
Proxy Filing - Board backs all agenda items, including 11 director nominees and two employee plan amendments.RMD
Proxy Filing - FY26 saw 8% revenue growth, 16% EPS growth, and $1B returned to shareholders.RMD
Corporate presentation - Volume-driven growth, digital engagement, and portfolio shifts drive robust outlook.RMD
Morgan Stanley 24th Annual Global Healthcare Conference